bioRxivCancer BiologyPreprint
Inhibition of nonsense-mediated decay rescues functional p53β/γ isoforms in MDM2-amplified cancers
J. P. Gudikote, T. Cascone, A. Poteete, P. Sitthideatphaiboon, Q. Wu, N. Morikawa, F. Zhang, S. Peng, P. Tong, L. Li, L. Shen, M. Nilsson, P. Jones, E. P. Sulman, J. Wang, J.-C. Bourdon, F. M. Johnson, J. Heymach
Abstract
Common mechanisms for p53 loss in cancer include expression of MDM2 or the human papilloma virus (HPV)-encoded E6 protein which both mediate degradation of wild-type (WT) p53 (p53). Here, we show that two alternatively-spliced, functional, truncated isoforms of p53 (p53{beta} and p53{gamma}, containing exons 1-9 of the p53 gene) can be markedly upregulated by pharmacologic or genetic inhibition of nonsense mediated decay (NMD), a regulator of aberrant mRNA stability. These isoforms lack the MDM2 binding domain and hence have reduced susceptibility to MDM2-mediated degradation. In MDM2-overexpressing cells bearing wildtype TP53 gene, NMD blockade increased p53{beta}/{gamma} expression and p53 pathway activation, enhanced radiosensitivity, and inhibited tumor growth. A similar pattern was observed in HPV+ cancer cells and in cancer cells with p53 mutations downstream of exon 9. These results identify a novel therapeutic strategy for restoration of p53 function in tumors rendered p53 deficient through MDM2 overexpression, HPV infection, or certain p53 mutations.
- organism: human
- assay: proteomics
- research focus: cancer & tumor microenvironment
- research focus: drug response / drug discovery
- research focus: cell type annotation
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The research progress of p53 tumour suppressor activity controlled by Numb in triple-negative breast cancer
Jie Xian, Yu Cheng, … Youde Cao·Journal of Cellular and Molecular MedicinePeer-reviewed·Jun 5, 2020
- Δ133p53α and Δ160p53α isoforms of the tumor suppressor protein p53 exert dominant-negative effect primarily by co-aggregation
Liuqun Zhao, Tanel Punga, Suparna Sanyal·eLifePeer-reviewed·Apr 17, 2025
- A CANCER PERSISTENT DNA REPAIR CIRCUIT DRIVEN BY MDM2, MDM4 (MDMX), AND MUTANT P53 FOR RECRUITMENT OF MDC1 AND 53BP1 TO CHROMATIN
V. Ellison, A. Polotskaia, … J. Bargonetti·bioRxiv·Jan 20, 2024
- Inhibition of nonsense-mediated mRNA decay reduces the tumorigenicity of human fibrosarcoma cells
Sofía Nasif, Martino Colombo, … Oliver Mühlemann·NAR CancerPeer-reviewed·Jun 9, 2023
- Targeting MDM2 homodimer and heterodimer disruption with DRx-098D in TP53 wild-type and mutant cancer cells
Sean F Cooke, Thomas A. Wright, … Connor M. Blair·Molecular Therapy OncologyPeer-reviewed·Aug 6, 2025
- Reactivation of TAp73 tumor suppressor by protoporphyrin IX, a metabolite of aminolevulinic acid, induces apoptosis in TP53-deficient cancer cells
A. Sznarkowska, A. Kostecka, … J. Zawacka-Pankau·bioRxiv·Aug 15, 2018